Market Cap 19.92M
Revenue (ttm) 0.00
Net Income (ttm) -25.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 165,500
Avg Vol 371,242
Day's Range N/A - N/A
Shares Out 17.48M
Stochastic %K 50%
Beta 0.64
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
frankinsense69
frankinsense69 Jul. 31 at 9:54 PM
$CVM $15M offering! Laughing
0 · Reply
DeepThought
DeepThought Jul. 31 at 7:50 PM
$CVM @BioGLovesMe Didn’t find a doctor? No doctor means no pills! Things are going to get really nasty for you.
0 · Reply
chaerophon
chaerophon Jul. 31 at 5:39 PM
2 · Reply
BioGLovesMe
BioGLovesMe Jul. 31 at 5:34 PM
$CVM "The bashers look rather foolish" while CVM's share price is near all time lows, the Saudi farce is about to turn 1 year old, the "confirmatory trial" still hasn't started, and they have less than two quarters' worth of operating capital left. You know they're desperate when they have to go digging in the giant turd to find a speck of gold: "Look guys, a journal publication of the datamined target population!" How nice, as you sit on your double digit averages waiting for a miracle that will never come.
0 · Reply
BioGLovesMe
BioGLovesMe Jul. 31 at 5:25 PM
$CVM Getting your clinical trial into a journal is NOT a positive development. Let's not forget it took multiple years from the conclusion of the P3 trial for the data to actually make it into a journal, let alone this new datamined population. Here's a timeline for the simple: June 2021: First disclosure of topline data fail. August 2022: Last update to clinicaltrials.gov March 2025: Peer-reviewed data finally published in a journal. That's nearly 4 years: most studies get peer-reviewed and published in 6-12 months after the trial concludes.
0 · Reply
itsverified
itsverified Jul. 31 at 3:46 PM
$CVM added a few more for the heck of it. 🤷‍♂️
2 · Reply
DeepThought
DeepThought Jul. 31 at 10:38 AM
$CVM Well, now the bashers look rather foolish. Multikine was peer‑reviewed and accepted for the exact same target population used in the Confirmatory Study and by a top‑tier peer‑review journal in head and neck oncology!💪😎 That’s not speculation, that’s a formal scientific validation!
0 · Reply
DeepThought
DeepThought Jul. 31 at 10:35 AM
$CVM @JohnHale6 If someone believes “Multikine alone could cure cancer in 2–3 months”, then the burden of proof is enormous. To demonstrate that, CEL‑SCI would need to run a completely new, standalone clinical program, because Multikine has never been tested as a monotherapy. We are talking about at least 5–8 years and roughly $200 million USD in development costs!
1 · Reply
JohnHale6
JohnHale6 Jul. 31 at 7:02 AM
$CVM Using MK for just a few weeks before surgery or radiation, put you in a group of 73% of survivors. Whereas if you only got the placebo and S of C there were 45% survivors. The drug is obviously effective, with a clear increase in life and cancer tumors shrinking. However at this point we have to use it “WITH” the standard of care. I believe if you were allowed to get only MK for two to Three months, you would beat cancer on your own without any other toxic treatment! When this is discovered to be true, it will do well over $40 billion a year in sales. This will replace Chemo. Whoever the big dog is who buys MK from CVm will be the big winner. They’ll probably pick it up for $12 billion. Then a few years later, they will be doing about $40 billion a year in sales. There’s definitely a lot of money to be made with this drug and a lot of good to do and a lot of lives to save. I am accumulating slowly, but I will be dumping a ton in a few months.
0 · Reply
DeepThought
DeepThought Jul. 31 at 3:52 AM
$CVM The SFDA will gladly incorporate this accepted Oral Oncology publication into their decision. Not as a requirement, but as an external validation that reinforces the strength of the data they already reviewed!
0 · Reply
Latest News on CVM
CEL-SCI Announces Closing of Offering

Jun 16, 2026, 4:01 PM EDT - 6 weeks ago

CEL-SCI Announces Closing of Offering


CEL-SCI highlights dual-track strategy for Multikine

2026-06-16T12:14:11.000Z - 6 weeks ago

CEL-SCI highlights dual-track strategy for Multikine


CEL-SCI Corporation Announces Pricing of Offering

Jun 14, 2026, 7:03 PM EDT - 6 weeks ago

CEL-SCI Corporation Announces Pricing of Offering


CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year

2026-05-18T12:10:09.000Z - 2 months ago

CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year


CEL-SCI Reports Fiscal Second Quarter 2026 Results

May 18, 2026, 8:00 AM EDT - 2 months ago

CEL-SCI Reports Fiscal Second Quarter 2026 Results


CEL-SCI Announces Closing of Public Offering

May 13, 2026, 3:00 PM EDT - 2 months ago

CEL-SCI Announces Closing of Public Offering


CEL-SCI 6M share Secondary priced at $1.20

2026-05-12T02:55:09.000Z - 2 months ago

CEL-SCI 6M share Secondary priced at $1.20


CEL-SCI Corporation Announces Pricing of Public Offering

May 11, 2026, 8:11 PM EDT - 2 months ago

CEL-SCI Corporation Announces Pricing of Public Offering


CEL-SCI files to sell 3.44M shares of common stock

2026-04-17T21:13:20.000Z - 3 months ago

CEL-SCI files to sell 3.44M shares of common stock


CEL-SCI Reports Fiscal First Quarter 2026 Results

Feb 18, 2026, 9:00 AM EST - 5 months ago

CEL-SCI Reports Fiscal First Quarter 2026 Results


CEL-SCI Reports Fiscal 2025 Results

Dec 29, 2025, 9:00 AM EST - 7 months ago

CEL-SCI Reports Fiscal 2025 Results


CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10 Million Public Offering


CEL-SCI 1.11M share Spot Secondary priced at $9.00

2025-08-28T03:45:10.000Z - 1 year ago

CEL-SCI 1.11M share Spot Secondary priced at $9.00


CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $10 Million Public Offering


CEL-SCI announces common stock offering, no amount given

2025-08-27T21:30:16.000Z - 1 year ago

CEL-SCI announces common stock offering, no amount given


CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 1 year ago

CEL-SCI Announces Proposed Public Offering


CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year

2025-08-14T14:50:29.000Z - 1 year ago

CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year


CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results


CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 1 year ago

CEL-SCI Announces Pricing of Public Offering


CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 1 year ago

CEL-SCI Announces Combination of Common Stock


CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results


CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering


CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering


CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering


CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering


CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock


CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 2 years ago

CEL-SCI Announces Closing of $10.8 Million Offering


frankinsense69
frankinsense69 Jul. 31 at 9:54 PM
$CVM $15M offering! Laughing
0 · Reply
DeepThought
DeepThought Jul. 31 at 7:50 PM
$CVM @BioGLovesMe Didn’t find a doctor? No doctor means no pills! Things are going to get really nasty for you.
0 · Reply
chaerophon
chaerophon Jul. 31 at 5:39 PM
2 · Reply
BioGLovesMe
BioGLovesMe Jul. 31 at 5:34 PM
$CVM "The bashers look rather foolish" while CVM's share price is near all time lows, the Saudi farce is about to turn 1 year old, the "confirmatory trial" still hasn't started, and they have less than two quarters' worth of operating capital left. You know they're desperate when they have to go digging in the giant turd to find a speck of gold: "Look guys, a journal publication of the datamined target population!" How nice, as you sit on your double digit averages waiting for a miracle that will never come.
0 · Reply
BioGLovesMe
BioGLovesMe Jul. 31 at 5:25 PM
$CVM Getting your clinical trial into a journal is NOT a positive development. Let's not forget it took multiple years from the conclusion of the P3 trial for the data to actually make it into a journal, let alone this new datamined population. Here's a timeline for the simple: June 2021: First disclosure of topline data fail. August 2022: Last update to clinicaltrials.gov March 2025: Peer-reviewed data finally published in a journal. That's nearly 4 years: most studies get peer-reviewed and published in 6-12 months after the trial concludes.
0 · Reply
itsverified
itsverified Jul. 31 at 3:46 PM
$CVM added a few more for the heck of it. 🤷‍♂️
2 · Reply
DeepThought
DeepThought Jul. 31 at 10:38 AM
$CVM Well, now the bashers look rather foolish. Multikine was peer‑reviewed and accepted for the exact same target population used in the Confirmatory Study and by a top‑tier peer‑review journal in head and neck oncology!💪😎 That’s not speculation, that’s a formal scientific validation!
0 · Reply
DeepThought
DeepThought Jul. 31 at 10:35 AM
$CVM @JohnHale6 If someone believes “Multikine alone could cure cancer in 2–3 months”, then the burden of proof is enormous. To demonstrate that, CEL‑SCI would need to run a completely new, standalone clinical program, because Multikine has never been tested as a monotherapy. We are talking about at least 5–8 years and roughly $200 million USD in development costs!
1 · Reply
JohnHale6
JohnHale6 Jul. 31 at 7:02 AM
$CVM Using MK for just a few weeks before surgery or radiation, put you in a group of 73% of survivors. Whereas if you only got the placebo and S of C there were 45% survivors. The drug is obviously effective, with a clear increase in life and cancer tumors shrinking. However at this point we have to use it “WITH” the standard of care. I believe if you were allowed to get only MK for two to Three months, you would beat cancer on your own without any other toxic treatment! When this is discovered to be true, it will do well over $40 billion a year in sales. This will replace Chemo. Whoever the big dog is who buys MK from CVm will be the big winner. They’ll probably pick it up for $12 billion. Then a few years later, they will be doing about $40 billion a year in sales. There’s definitely a lot of money to be made with this drug and a lot of good to do and a lot of lives to save. I am accumulating slowly, but I will be dumping a ton in a few months.
0 · Reply
DeepThought
DeepThought Jul. 31 at 3:52 AM
$CVM The SFDA will gladly incorporate this accepted Oral Oncology publication into their decision. Not as a requirement, but as an external validation that reinforces the strength of the data they already reviewed!
0 · Reply
Johnyd
Johnyd Jul. 31 at 1:53 AM
$CVM puffy:navy davy de clara is sushi! as is bloody mon declara (the female sushi?)super mario de clara(strong suspect),baby declara ,dr Twiddle de clara(maybe...)
0 · Reply
Johnyd
Johnyd Jul. 31 at 1:45 AM
$CVM' ......For 5 years a cabal of short sellers using naked short selling , spoofing and lies told you the trial failed....." hhahahahahhahaha1
1 · Reply
k3vl4r
k3vl4r Jul. 30 at 10:25 PM
What do you think of the 1609/1845 scan? I’m watching $CVM, $YRD, and $TTD for a push tomorrow. Any calls on the bearish names? #stocks #investing
0 · Reply
frankinsense69
frankinsense69 Jul. 30 at 9:26 PM
$CVM clearly dilution tomorrow
0 · Reply
k3vl4r
k3vl4r Jul. 30 at 9:11 PM
$CVM just hit 100% bullish on the 1h-1wk horizon. It’s one of K3vl4r’s top picks for tomorrow’s session. Keep an eye on the trade, could be a solid end-of-day watch. #stocks #StockMarket
1 · Reply
DeepThought
DeepThought Jul. 30 at 8:24 PM
0 · Reply
DeepThought
DeepThought Jul. 30 at 8:23 PM
$CVM @BioGLovesMe Seek professional help! Your brain is clearly malfunctioning.
0 · Reply
BioGLovesMe
BioGLovesMe Jul. 30 at 6:09 PM
$CVM Tomorrow is "Tar and Feather" day for everyones favorite permabaggie. In lieu of bowing down to me and admitting you were wrong (as we all know you were) please buy more CVM shares instead. Also provide proof of your TOTAL position and average. Love you.
0 · Reply
chaerophon
chaerophon Jul. 30 at 3:47 PM
$CVM The SFDA's scientific bonafides would be enhanced if their BMD for Multikine did not follow the publication like a curtsey, but rather preceded it with instructing regulatory expectations.
2 · Reply
prophet777
prophet777 Jul. 30 at 3:46 PM
$CVM didn’t even move the needle… Geert good try only 2 years behind… so we can expect dilution tomorrow following your usual scheme…
0 · Reply
chaerophon
chaerophon Jul. 30 at 2:52 PM
2 · Reply
Kensfuqt
Kensfuqt Jul. 30 at 2:19 PM
0 · Reply